Anhui Fengyuan Pharmaceutical Co Ltd (SHE:000153) — Market Cap & Net Worth
Market Cap & Net Worth: Anhui Fengyuan Pharmaceutical Co Ltd (000153)
Anhui Fengyuan Pharmaceutical Co Ltd (SHE:000153) has a market capitalization of $446.07 Million (CN¥3.05 Billion) as of April 11, 2026. Listed on the SHE stock exchange, this China-based company holds position #14284 globally and #3988 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Anhui Fengyuan Pharmaceutical Co Ltd's stock price CN¥6.56 by its total outstanding shares 464685522 (464.69 Million).
Anhui Fengyuan Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Anhui Fengyuan Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $461.03 Million to $446.07 Million (-0.31% CAGR).
Anhui Fengyuan Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Anhui Fengyuan Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.10x
Anhui Fengyuan Pharmaceutical Co Ltd's market cap is 0.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.59x
Anhui Fengyuan Pharmaceutical Co Ltd's market cap is 2.59 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $461.03 Million | $1.55 Billion | $32.39 Million | 0.30x | 14.23x |
| 2016 | $576.71 Million | $2.03 Billion | $45.84 Million | 0.28x | 12.58x |
| 2017 | $353.90 Million | $2.58 Billion | $65.35 Million | 0.14x | 5.42x |
| 2018 | $230.42 Million | $3.01 Billion | $60.93 Million | 0.08x | 3.78x |
| 2019 | $302.66 Million | $3.24 Billion | $80.92 Million | 0.09x | 3.74x |
| 2020 | $402.94 Million | $3.32 Billion | $103.72 Million | 0.12x | 3.88x |
| 2021 | $548.55 Million | $3.50 Billion | $122.98 Million | 0.16x | 4.46x |
| 2022 | $631.55 Million | $4.00 Billion | $154.43 Million | 0.16x | 4.09x |
| 2023 | $442.76 Million | $4.28 Billion | $159.29 Million | 0.10x | 2.78x |
| 2024 | $416.83 Million | $4.28 Billion | $160.83 Million | 0.10x | 2.59x |
Competitor Companies of 000153 by Market Capitalization
Companies near Anhui Fengyuan Pharmaceutical Co Ltd in the global market cap rankings as of April 11, 2026.
Key companies related to Anhui Fengyuan Pharmaceutical Co Ltd by market ranking:
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #438 globally with a market cap of $53.17 Billion USD ( CN¥363.35 Billion CNY).
- Zoetis Inc (NYSE:ZTS): Ranked #442 globally with a market cap of $52.88 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #494 globally with a market cap of $47.47 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #512 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #438 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $53.17 Billion | CN¥56.96 |
| #442 | Zoetis Inc | NYSE:ZTS | $52.88 Billion | $119.99 |
| #494 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #512 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $39.89 |
Anhui Fengyuan Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Anhui Fengyuan Pharmaceutical Co Ltd's market cap moved from $461.03 Million to $ 446.07 Million, with a yearly change of -0.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥446.07 Million | +4.63% |
| 2025 | CN¥426.35 Million | +2.28% |
| 2024 | CN¥416.83 Million | -5.86% |
| 2023 | CN¥442.76 Million | -29.89% |
| 2022 | CN¥631.55 Million | +15.13% |
| 2021 | CN¥548.55 Million | +36.14% |
| 2020 | CN¥402.94 Million | +33.13% |
| 2019 | CN¥302.66 Million | +31.35% |
| 2018 | CN¥230.42 Million | -34.89% |
| 2017 | CN¥353.90 Million | -38.63% |
| 2016 | CN¥576.71 Million | +25.09% |
| 2015 | CN¥461.03 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 10th, 2026 the market cap of Anhui Fengyuan Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $446.07 Million USD |
| MoneyControl | $446.07 Million USD |
| MarketWatch | $446.07 Million USD |
| marketcap.company | $446.07 Million USD |
| Reuters | $446.07 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Anhui Fengyuan Pharmaceutical Co Ltd
Anhui Fengyuan Pharmaceutical Co., Ltd. researches and develops, produces, and sells medicines in China. The company also exports its products. Anhui Fengyuan Pharmaceutical Co., Ltd. was incorporated in 1997 and is based in Hefei, China.